Accuracy That Inspires Confidence. Speed That Saves Lives. Early HIV detection starts with a diagnostic test you can trust. The Wondfo One Step HIV 1/2 Rapid Test delivers: ✅ 100% Sensitivity ✅ 99.96% Specificity ✅ WHO Prequalified ✅ 3rd Generation Technology (IgM & IgG Detection) ✅ Results in Just 15 Minutes ✅ Compatible with Whole Blood, Serum & Plasma Designed for laboratories, hospitals, blood banks, and healthcare professionals who demand reliable performance and rapid clinical decisions. At ABC Corporation, we're committed to bringing world-class diagnostic solutions to improve patient care. Reliable Diagnostics. Faster Decisions. Better Healthcare. #HIVTesting #RapidDiagnostics #Wondfo #LaboratoryMedicine #ClinicalDiagnostics #POCT #Healthcare #MedicalLaboratory #Diagnostics #ABCCorporation

A new modeling study in JAMA Network Open puts hard numbers on a trend healthcare leaders should be watching closely: the aging HIV population within Medicare. Key projections for 2026-2035: - Medicare beneficiaries 65+ with HIV: 122,000 → ~194,000 - Cumulative Medicare cost: $187.2 billion - Antiretroviral therapy alone: 63% of that spending The study's authors point to drug pricing policy, including IRA negotiation and upcoming generic competition, as key levers to manage this cost trajectory. But they also flag a tradeoff worth watching: potential downstream effects on the 340B program, which many HIV care organizations rely on for funding. Full analysis in our latest coverage https://hubs.li/Q04p3jM60

🩺 New publication: Single dose or three weekly doses of benzathine penicillin G for early syphilis? Our systematic review and meta-analysis evaluates the efficacy and safety of single-dose versus three-dose benzathine penicillin G (BPG) for the treatment of early syphilis. Highlights: 💉 No significant difference in serological cure between single-dose and three-dose BPG in the primary intention-to-treat analysis 🦠 Findings support current CDC and WHO recommendations for single-dose treatment, including for people with HIV 🔬 Exploratory analyses suggested possible benefits of three doses in patients with high baseline RPR titers or early latent syphilis, but the evidence was of very low certainty 📊 The review underscores the need for adequately powered, high-quality clinical trials before considering dose stratification Overall, the available evidence supports single-dose BPG as the standard treatment for most patients with early syphilis, while highlighting important areas for future research. 📖 Read the full article: https://lnkd.in/gnSXyzdU 👥 Thanyarat Phumthian, Sudapree Sorasuchart, Samadhi Patamatamkul #Syphilis #InfectiousDiseases #EvidenceBasedMedicine #MetaAnalysis #AntimicrobialStewardship #HIV #MedicalResearch

Local health departments (LHDs) are increasingly advancing syndemic approaches to address the intersecting epidemics of STIs, HIV, viral hepatitis, and related health and social conditions. However, current reporting systems and metrics are often siloed by disease area and funding stream, making it difficult to capture the integrated, longitudinal, and relationship-based nature of this work. This issue brief explores challenges LHDs face in documenting and evaluating syndemic approaches, including duplicative reporting requirements, fragmented data systems, and metrics that may not capture the relationship-building, coordination, and sustained engagement that support better health outcomes or show whether services are reaching communities most impacted by the syndemic. https://lnkd.in/eXW_Xgze

🧬 Understanding HIV/AIDS: From Infection to Immune System Impact HIV primarily targets CD4 (T-helper) cells, gradually weakening the immune system and increasing vulnerability to opportunistic infections and certain cancers. Understanding its transmission, pathogenesis, diagnosis, prevention, and treatment is essential for healthcare professionals and the wider community. 💡 Key message: With early diagnosis and effective antiretroviral therapy (ART), people living with HIV can lead long, healthy lives. Undetectable = Untransmittable (U=U) through sexual transmission. Knowledge reduces stigma. Awareness strengthens prevention. Science saves lives. 🧪🔬 #HIV #AIDS #HIVAwareness #MedicalLaboratoryScience #ClinicalLaboratory #Microbiology #Immunology #ART #PublicHealth #HealthcareEducation #LaboratoryMedicine #MedicalEducation #BScMLS #MedTech

The iCARE HIV Ag/Ab Tri-line Rapid Test is developed for professional in vitro diagnostic use and evaluated to support reliable testing performance. During validation, the assay was tested against multiple potential interfering conditions, with no cross-reactivity observed under the evaluated conditions. Each test also incorporates an internal quality control line to support test verification and quality assurance during use. For more details, Visit: https://lnkd.in/gUTnfTRr #JALMedicalSingaporePteLtd #JalMedical #HIVAgAbTriLineRapidTestKit #HIVTest #NoCrossReactivity #ClinicalValidation #InVitroDiagnostics #DiagnosticIntegrity #MedicalAccuracy #RapidDiagnostics #QualityControl

🌍 Ending HIV, Hepatitis & STIs Requires More Than Medicine—It Requires Collaboration. Global health has made remarkable progress over the past decade. Millions more people now have access to HIV treatment, new infections have declined, and advances in prevention and diagnostics continue to transform healthcare. However, progress is not guaranteed. Funding challenges, health in equalities, rising antimicrobial resistance, and limited access to essential healthcare services continue to slow the fight against HIV, viral hepatitis, and sexually transmitted infections (STIs). The way forward is clear: ✔️ Stronger primary healthcare systems ✔️ Integrated disease prevention and treatment ✔️ Community-led healthcare initiatives ✔️ Digital health and smarter surveillance ✔️ Equitable access to innovative medicines, diagnostics, and preventive technologies Achieving the global goal of eliminating these diseases as public health threats by 2030 will require sustained commitment from governments, healthcare professionals, researchers, policymakers, and communities worldwide. As future healthcare professionals, we all have a role in promoting awareness, supporting evidence-based practices, and contributing to stronger public health systems. Healthy communities begin with accessible, inclusive, and innovative healthcare. #WHO #PublicHealth #HIV #Hepatitis #STI #GlobalHealth #Healthcare #DiseasePrevention #HealthEquity #PrimaryHealthcare #DigitalHealth #MedicalResearch #PharmaceuticalIndustry #Pharmacy #FuturePharmacist

I spent time in the tesamorelin literature last week because the mechanism is genuinely interesting. It tells your pituitary to release growth hormone naturally instead of relying on exogenous hormone replacement. Two large Phase III trials in 806 HIV patients showed 15 to 18% reductions in visceral fat over 26 weeks versus placebo. That's the strongest evidence base any GHRH analogue has. The glucose safety profile held solid across the pooled data, which matters because most people worry about GH and metabolic disruption. The honest nuance: that evidence is visceral-fat-specific and mostly HIV-lipodystrophy patients. The mechanism supports broader use in healthy men, but anyone extrapolating the trial data to a general population is making an inference, not citing a trial. Off-label interest is climbing, but the randomised data in non-HIV adults is thin. What's your threshold for evidence when you're considering a compound off-label? Do you need human trials, or does mechanism plus safety data move you forward? If you're serious about protocols, the cycle-plan builder walks you through dosing, timing, and stacking frameworks: https://lnkd.in/gGYsZuJi

Last week Thursday (2 July 2026) I started this Medical Outcomes Study-HIV Study (MOS-HIV) with University of Botswana (School of Medicine). The objective of this study is to measure health related quality of life among People Living With HIV (PLHIV), and doing so by adopting the already existing tool to Tswana version. 📚 At the end, this tool has to be integrated into current IDCC services for PLHIV to improve their health holistically. My observations so far is that: - Participants are a bit hesitant and resistant to take part, that in-turn makes it hard to reach the target. - Some I also noticed that they wont participate if there's nothing directly of benefit to them. This is a lesson of researchers. 1. Cultural and societal expectations are a constant barrier to development research🧐 2. Anticipated benefits dont always translate to perceived benefit of research i.e what participants are looking for, is not always what the researchers are offering at hand.💸 The solution is 1. For every research, the target groups should go through proper orientation and research education. This helps to answer questions and clear any ambiguity before the exercise.✍️ 2. There's a need also for robust mindset change in our communities; it is not enough to share the benefits of the research to participants, there's a need for assurance and making participants see the need to be change makers, to be part and parcel of the development they want to see.🤔 Let me know what you think, or share your research experiences on the comment box below👇

What does a timeline built for urgency look like? It started with an access strategy developed years before the U.S. FDA approval of our twice-yearly HIV prevention medicine so supply could move quickly and scale over time. This included clinical research, manufacturing preparation, voluntary licensing agreements, technology transfer and global partnerships designed to help accelerate access. Every moment behind this milestone moved the strategy forward and keeps us focused on ensuring this medicine reaches the communities that need it most.